Rick E. Blakesley

1.9k total citations
24 papers, 1.4k citations indexed

About

Rick E. Blakesley is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Rick E. Blakesley has authored 24 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 14 papers in Hematology and 7 papers in Rheumatology. Recurrent topics in Rick E. Blakesley's work include Chronic Lymphocytic Leukemia Research (14 papers), Chronic Myeloid Leukemia Treatments (14 papers) and Eosinophilic Disorders and Syndromes (7 papers). Rick E. Blakesley is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Chronic Myeloid Leukemia Treatments (14 papers) and Eosinophilic Disorders and Syndromes (7 papers). Rick E. Blakesley collaborates with scholars based in United States, Italy and Switzerland. Rick E. Blakesley's co-authors include Andreas Hochhaus, Neil J. Gallagher, Richard A. Larson, Timothy P. Hughes, Giuseppe Saglio, Hagop M. Kantarjian, Ian W. Flinn, Gianantonio Rosti, Michele Baccarani and Philipp D. le Coutre and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Rick E. Blakesley

24 papers receiving 1.4k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Rick E. Blakesley	1.1k	965	625	170	124	24	1.4k
Carolina Pavlovsky	890 0.8×	749 0.8×	456 0.7×	161 0.9×	106 0.9×	36	1.0k
Marianne Rosamilia	483 0.4×	309 0.3×	215 0.3×	119 0.7×	93 0.8×	7	684
Agnès Guerci	1.9k 1.7×	1.3k 1.4×	666 1.1×	247 1.5×	235 1.9×	49	2.1k
Luciano Levato	268 0.2×	440 0.5×	82 0.1×	128 0.8×	43 0.3×	39	659
Prasheen Agarwal	971 0.9×	510 0.5×	1.0k 1.7×	102 0.6×	88 0.7×	29	1.7k
Rebecca Wood	237 0.2×	168 0.2×	126 0.2×	213 1.3×	38 0.3×	4	563
Giulia Benevolo	846 0.8×	511 0.5×	135 0.2×	436 2.6×	49 0.4×	54	1.2k
Jenny Shan	1.2k 1.0×	923 1.0×	608 1.0×	121 0.7×	149 1.2×	26	1.3k
Agnès Guerci‐Bresler	1.4k 1.2×	1.1k 1.2×	546 0.9×	237 1.4×	111 0.9×	53	1.5k
Marek Hus	461 0.4×	239 0.2×	97 0.2×	319 1.9×	22 0.2×	110	869

Countries citing papers authored by Rick E. Blakesley

Since Specialization

Citations

This map shows the geographic impact of Rick E. Blakesley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rick E. Blakesley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rick E. Blakesley more than expected).

Fields of papers citing papers by Rick E. Blakesley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rick E. Blakesley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rick E. Blakesley. The network helps show where Rick E. Blakesley may publish in the future.

Co-authorship network of co-authors of Rick E. Blakesley

This figure shows the co-authorship network connecting the top 25 collaborators of Rick E. Blakesley. A scholar is included among the top collaborators of Rick E. Blakesley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rick E. Blakesley. Rick E. Blakesley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tournev, Ivailo, Mark Taylor, Teresa Coelho, et al.. (2021). HELIOS-A: 9-month results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Journal of the Neurological Sciences. 429. 117767–117767. 4 indexed citations

Adams, David, Ivailo Tournev, Mark Taylor, et al.. (2021). HELIOS-A: 9-month Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (1234). Neurology. 96(15_supplement). 6 indexed citations

Brenner, Darren M., Charles E. Argoff, Susan M. Fox, et al.. (2020). Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study. Pain. 161(5). 1027–1036. 10 indexed citations

Simon, James A., William H. Catherino, James H. Segars, et al.. (2018). Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas. Obstetrics and Gynecology. 131(3). 431–439. 39 indexed citations

Schoenfeld, Philip, Brian E. Lacy, William D. Chey, et al.. (2017). Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. The American Journal of Gastroenterology. 113(1). 105–114. 55 indexed citations

Simon, James A., et al.. (2017). Ulipristal Acetate Treatment of Uterine Fibroids in Black and Obese Women: Venus I Subgroup Analyses [28G]. Obstetrics and Gynecology. 129(1). 78S–79S. 4 indexed citations

Simon, James A., William H. Catherino, James H. Segars, et al.. (2016). First US-based phase 3 study of ulipristal acetate (UPA) for symptomatic uterine fibroids (UF): results of VENUS-I. Fertility and Sterility. 106(3). e376–e376. 12 indexed citations

Lacy, Brian E., Ron Schey, Steven J. Shiff, et al.. (2015). Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial. PLoS ONE. 10(7). e0134349–e0134349. 56 indexed citations

Shaw, Alice T., Tony Mok, David R. Spigel, et al.. (2013). A phase II single-arm study of LDK378 in patients with ALK-activated (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).. Journal of Clinical Oncology. 31(15_suppl). TPS8119–TPS8119. 7 indexed citations

10.

Larson, Richard A., Andreas Hochhaus, Timothy P. Hughes, et al.. (2012). Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 26(10). 2197–2203. 323 indexed citations

11.

Coutre, Philipp D. le, Francis J. Giles, Andreas Hochhaus, et al.. (2011). Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 26(6). 1189–1194. 63 indexed citations

12.

Kantarjian, Hagop M., Andreas Hochhaus, Giuseppe Saglio, et al.. (2011). Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. The Lancet Oncology. 12(9). 841–851. 377 indexed citations

13.

Giles, Francis J., Hagop M. Kantarjian, Philipp D. le Coutre, et al.. (2011). Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 26(5). 959–962. 67 indexed citations

14.

Saglio, Giuseppe, Ricardo Pasqüini, Saengsuree Jootar, et al.. (2011). Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up. Blood. 118(21). 452–452. 10 indexed citations

15.

Larson, Richard A., Udomsak Bunworasate, Anna Turkina, et al.. (2011). Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,. Blood. 118(21). 3768–3768. 8 indexed citations

16.

Beaumont, Jennifer L., Cindy J. Nowinski, John Coombs, et al.. (2011). Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?. Blood. 118(21). 1025–1025. 1 indexed citations

17.

Larson, Richard A., Gianantonio Rosti, Rick E. Blakesley, et al.. (2011). Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up.. Journal of Clinical Oncology. 29(15_suppl). 6511–6511. 8 indexed citations

18.

Cortes, Jörge E., Andreas Hochhaus, Philipp D. le Coutre, et al.. (2011). Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood. 117(21). 5600–5606. 51 indexed citations

19.

Kantarjian, Hagop M., Francis J. Giles, Kapil N. Bhalla, et al.. (2010). Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 117(4). 1141–1145. 271 indexed citations

20.

Giles, Frank, Hagop M. Kantarjian, Phillipp D. Le Coutre, et al.. (2010). Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib.. Journal of Clinical Oncology. 28(15_suppl). 6510–6510. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact